drugset / Trial / NCT07201558
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
Non-randomizedSequentialOpen-labelTreatment
Summary
This open-label, Phase I study will assess the safety and tolerability of surovatamig and characterise its PK and PD following subcutaneous administration to participants with RA or SLE.
Timeline
- Start
- 2025-12-02
- Primary completion
- 2028-06-27
- Completion
- 2028-06-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Surovatamig | Protein / enzyme biologic | — | Subcutaneous |